Idorsia Ltd (19T.SG)
| Previous close | 19.80 |
| Open | 17.78 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.78 - 18.42 |
| 52-week range | 17.78 - 19.80 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Idorsia announces the results of REACT a Phase 3 study of clazosentan in patients following aneurysmal subarachnoid hemorrhage
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – February 6, 2023 Idorsia Ltd (SIX: IDIA) today announces the initial findings of REACT, a Phase 3 study which investigated the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia, in patients following aneurysmal subarachnoid hemorrhage (aSAH). The study did not meet the primary endpoint. The company will fully analyze the efficacy and safety data to understand this unexpected
- GlobeNewswire
Invitation to Idorsia's full year financial results 2022 webcast and conference call
Idorsia will publish its full year financial results 2022 on Tuesday February 7, 2023, at 07:00 CET An investor conference call and webcast will be held to discuss the results on the same day. Date: Tuesday, February 7, 2023 Time: 14:00 CET / 13:00 GMT / 08:00 EST The call will start with presentations by senior management, followed by a Q&A session. To support your preparations, the consensus estimates can be found under: www.idorsia.com/consensus-estimate. Dial-in procedure: 1) Participants ar
- GlobeNewswire
Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension
The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – January 31, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for aprocitentan, Idorsia’s investigational, novel dual endothelin receptor antagonist, for the trea
